8-K: Endovia Health Sciences Reports Unregistered Equity Sale

Endovia Health Sciences disclosed the sale of 526,582 shares of common stock for gross proceeds of $81,830.84 under an existing agreement.

Summary

• Endovia Health Sciences, Inc. reported the sale of 526,582 shares of its common stock on September 30, 2026.
• The sale generated gross proceeds of $81,830.84.
• These shares were sold under a Securities Purchase Agreement with C/M Capital Master Fund, LP, previously disclosed.
• The sales were conducted under the exemption provided by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b).
• The company's registration statement on Form S-1, which covers resales of these shares, became effective on August 24, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the unregistered sale of equity securities at a low price, indicating potential financial distress or a need for immediate capital.

Positives

• The company successfully raised $81,830.84 in gross proceeds.
• The sale was conducted under an existing agreement, suggesting a pre-established financing mechanism.
• The resales of the shares are registered, providing a path for liquidity for the purchaser.

Negatives

• The sale involved unregistered equity securities, which can be a sign of financial pressure.
• The average price per share was approximately $0.155 ($81,830.84 / 526,582 shares), which is very low and dilutive.
• The company continues to rely on equity sales under an agreement that was previously disclosed, potentially indicating ongoing capital needs.

Risks

• Continued reliance on unregistered equity sales could signal ongoing financial difficulties.
• Significant dilution to existing shareholders due to low-priced equity issuances.
• Potential for further downward pressure on the stock price if more sales occur under the agreement.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, the continued reliance on equity sales under the ELOC Agreement suggests an ongoing need for capital.

Management Comments

• The Company sold and issued a total of 526,582 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master Fund, LP as purchaser (the ELOC Agreement) for total gross proceeds of $81,830.84.

Industry Context

StockSavvy.ai notes that the sale of unregistered equity securities, especially at a low per-share price, is often indicative of companies facing liquidity challenges or seeking to finance operations when traditional debt or equity markets are less accessible. This practice can lead to significant dilution for existing shareholders.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the low price per share of the newly issued stock.
• Creditors: May view continued reliance on equity sales as a sign of financial instability.

Next Steps

• The purchasers' resales of the shares were registered on the Company's registration statement on Form S-1, effective August 24, 2026, allowing for potential future market sales by the purchaser.

Key Dates

Recommendation

The sale of unregistered equity at a deeply discounted price, as reported in this 8-K, signals potential financial distress and significant dilution for existing shareholders. This suggests a negative outlook for the stock's short-to-medium term performance.

Keywords

Equity Sale, Unregistered Securities, Capital Raise, Securities Purchase Agreement, Form S-1, Common Stock, C/M Capital Master Fund